{
  "_metadata": { "version": "2.1", "ticker": "ARGX", "asset_name": "ARGX-121", "extraction_date": "2026-02-11", "source_id": "argx_corporate_2026" },
  "asset": { "name": "ARGX-121", "company": "argenx SE", "ticker": "ARGX", "stage": "PoC (IgA Nephropathy)", "modality": "Antibody (IgA sweeping antibody with IgA-targeting Fab + Fc-ABDEG)", "ownership": null, "one_liner": "ARGX-121 is an IgA sweeping antibody that achieves rapid and total IgA depletion (~100% reduction) within 7 days, being developed for IgA nephropathy and 3+ potential indications." },
  "target": { "name": "IgA", "full_name": "Immunoglobulin A", "class": "Immunoglobulin", "pathway": "IgA-mediated immune response", "biology": { "simple_explanation": "IgA is an antibody type that can become pathogenic in diseases like IgA nephropathy, where abnormal IgA deposits in the kidneys cause damage. ARGX-121 sweeps IgA from the blood, potentially halting kidney damage and other IgA-mediated disease processes.", "pathway_detail": null, "downstream_effects": ["Rapid depletion of circulating IgA", "Potential reduction of pathogenic IgA deposits"] }, "why_good_target": { "clinical_validation": "Phase 1 showed rapid and total IgA depletion (~100% reduction from baseline within 7 days)", "genetic_validation": { "gain_of_function": null, "loss_of_function": null }, "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } },
  "mechanism": { "type": "IgA sweeping antibody", "how_it_works": "ARGX-121 uses an IgA-targeting Fab fragment combined with Fc-ABDEG technology to bind and sweep IgA from circulation, achieving rapid and total IgA depletion", "differentiation": "First IgA sweeping antibody; achieves ~100% IgA depletion within 7 days after single SC dose", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} },
  "regulatory": { "designations": null, "planned_pathway": { "type": null, "surrogate_endpoint": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} } },
  "partnership": { "_note": "No partnership information provided", "partner": null, "territory": null, "economics": null },
  "pharmacology": {
    "pk_parameters": { "half_life": { "value": null, "population": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "cmax": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "auc": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "tmax": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "bioavailability": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "volume_of_distribution": { "value": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} } },
    "dose_response": null,
    "target_engagement": {
      "metric": "IgA change from baseline (%)",
      "by_dose": [ { "dose": "Single dose SC", "engagement": "IgA reduction curve shown (slide 21) — ARGX-121 single dose SC achieves rapid ~100% IgA depletion from baseline within ~7 days, sustained through 28 days. Placebo showed no change (~0%). Graph shows IgA drops from 0% to approximately -100% by day 7 and remains at -100% through day 28.", "compartment": "blood", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } ]
    },
    "pk_summary": "Slide 21 shows ARGX-121 single dose SC achieves rapid and total IgA depletion (~-100% from baseline) within approximately 7 days, sustained through 28 days of follow-up. Placebo arm showed no change. Graph axes: Y-axis = IgA change from baseline (%), X-axis = time in days (0-28). No numeric PK parameters provided."
  },
  "indications": { "lead": { "name": "IgA Nephropathy", "patient_population": null, "current_penetration": null, "rationale": "IgA deposits in kidneys cause progressive damage; sweeping IgA may halt disease progression" }, "expansion": [ { "name": "3+ potential indications (not specified)", "stage": null, "rationale": null, "source": {"id": "argx_corporate_2026", "slide": 20, "verified": false} } ] },
  "clinical_data": { "trials": null, "_note": "Phase 1 data shown graphically (slide 21) — single dose SC in healthy volunteers vs placebo; no trial details provided" },
  "differentiation_claims": [ { "claim": "Rapid and total IgA depletion (~100% reduction within 7 days)", "evidence_level": "preclinical_only", "caveat": "Phase 1 healthy volunteer data only; single SC dose; small sample size (not specified); sustained through 28 days only", "source": {"id": "argx_corporate_2026", "slide": 21, "verified": false} } ],
  "competitive_landscape": { "competitors": null },
  "ip_landscape": { "composition_of_matter": { "patent_expiry": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "method_of_use": { "patent_expiry": null, "source": {"id": "argx_corporate_2026", "slide": null, "verified": false} }, "regulatory_exclusivity": { "type": null, "expiry": null }, "freedom_to_operate": null },
  "market_opportunity": { "tam": null, "patient_population": "3+ potential indications", "unmet_need": null, "pricing_benchmark": null, "peak_sales_estimate": null, "source": {"id": "argx_corporate_2026", "slide": 20, "verified": false} },
  "catalysts": null,
  "investment_analysis": { "probability_of_success": null, "key_risks": ["Very early stage (PoC)", "Healthy volunteer data only", "IgA depletion safety implications unknown"], "bull_case": [ {"thesis": "Rapid and total IgA depletion is a highly differentiated pharmacological profile", "evidence": "Phase 1 PD data (slide 21)", "confidence": "low"} ], "bear_case": [ {"thesis": "Early stage with no patient data; safety of complete IgA depletion uncertain", "evidence": "Phase 1 only", "confidence": "medium"} ], "key_debates": null },
  "_extraction_quality": { "completeness_score": "low", "missing_critical_fields": ["PK parameters", "Dosing details", "Safety data", "Trial enrollment", "Patient data (healthy volunteers only)", "Market opportunity", "IP/patents", "Development timeline"], "recommended_supplementary_sources": ["ARGX-121 Phase 1 publication or conference presentation", "argenx R&D Day for IgA nephropathy development plans"] }
}
